trial

The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine

NCTId NCT05213143
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 13 (actual)
Sponsored by Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Primary completion 2022-11-18
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
13 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2021-12-30
Primary completion
2022-11-18
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Lurasidone

Sponsors

Marubeni Pharmaceuticals (Suzhou) Co., Ltd.Lead Sponsor

Sites

1 total
Beijing, China

Facts & assertions

4 sourced
Enrollment
13
Phase
PHASE4
Primary Completion Date
2022-11-18
Status
TERMINATED
relationships
The graph out of here
drug
Lurasidone
drug
lead_sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication